Bristol Myers Squibb (BMY) Invested Capital (2009 - 2026)

Bristol Myers Squibb has disclosed Invested Capital across 18 years of filings, most recently posting $64.2 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 28.94% year-over-year to $64.2 billion; the TTM figure through Mar 2026 stood at $64.2 billion (up 28.94% YoY), while the FY2025 annual figure was $63.3 billion, down 1.62% from the prior year.
• Invested Capital climbed to $64.2 billion in Q1 2026, from $63.3 billion in the prior quarter.
• Over the last five years, Invested Capital for BMY reached as high as $67.3 billion in Q3 2025 and fell as low as -$2.6 billion in Q2 2023.
• The 5-year median for Invested Capital is $49.0 billion (2025), against an average of $43.2 billion.
• Annual changes were most pronounced in 2023 — Invested Capital sank 140.4% — and 2024, when it jumped 2101.61%.
• A 5-year view of Invested Capital shows it stood at $37.7 billion in 2022, then advanced by 0.82% to $38.0 billion in 2023, then surged by 69.41% to $64.3 billion in 2024, then fell by 1.62% to $63.3 billion in 2025, then advanced by 1.43% to $64.2 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $64.2 billion, $63.3 billion, and $67.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.